Lifitegrast For Solution
Product Images NDC 59651-450

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Lifitegrast (NDC 59651-450). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lifitegrast Ophthalmic Solution 5% Figure1 (Lifitegrast Fig1)

Four forest plots summarizing data from four studies comparing Vehicle and Lifitegrast groups at multiple visits. Each plot shows mean values with confidence intervals for both groups and the difference favoring Lifitegrast, with x-axes indicating the range from -20 to 5. The plots visualize the comparative effects of Lifitegrast versus Vehicle over time.*

FDA Label Image

Lifitegrast Ophthalmic Solution 5% Figure-10 (Lifitegrast Fig10)

An instructional illustration showing a person tilting their head back and using one hand to pull down the lower eyelid of their eye, while the other hand holds an eyedrop bottle above the eye to administer the ophthalmic solution.*

FDA Label Image

Lifitegrast Ophthalmic Solution 5% Figure11 (Lifitegrast Fig11)

Label for Lifitegrast Ophthalmic Solution 5%, an eye drop solution packaged in 5 single-dose containers of 0.2 mL each. The label includes instructions for use, storage conditions (20 to 25°C), and notes the product as sterile and preservative-free. Distributed by Aurobindo Pharma USA, Inc., the label also features the Aurobindo logo and relevant barcodes.*

FDA Label Image

Lifitegrast Ophthalmic Solution 5% Figure12 (Lifitegrast Fig12)

Lifitegrast 5% Ophthalmic Solution carton for topical eye application, containing 60 single-dose containers (0.2 mL each) in 12 pouches of 5 containers. Label shows NDC 59651-450-60, manufactured by Aurobindo Pharma Limited, distributed by Aurobindo Pharma USA, Inc. Storage and dosage instructions are partially visible.*

FDA Label Image

Lifitegrast Ophthalmic Solution 5% Figure2 (Lifitegrast Fig2)

Four forest plots from separate studies compare the effects of Lifitegrast 50 mg/mL ophthalmic solution versus vehicle on a numeric outcome across multiple visits (Baseline, Day 14, Day 42, Day 84). Each plot shows mean values, differences with 95% confidence intervals, and indicates whether results favor Lifitegrast. The data illustrate changes over time in each study population.*

FDA Label Image

Lifitegrast Ophthalmic Solution 5% Figure-3 (Lifitegrast Fig3)

An instructional illustration showing two hands opening a small packet or sachet by peeling apart the top seal. The image demonstrates how to open the packaging, likely for a single-dose ophthalmic solution.*

FDA Label Image

Lifitegrast Ophthalmic Solution 5% Figure-4 (Lifitegrast Fig4)

An instructional illustration labeled Figure B showing a hand holding a single-dose ophthalmic solution ampule, with four more ampules in a row next to it, demonstrating how to handle the Lifitegrast 50 mg/mL ophthalmic solution single-dose packaging.*

FDA Label Image

Lifitegrast Ophthalmic Solution 5% Figure-5 (Lifitegrast Fig5)

An instructional illustration showing two hands opening a foil packet, which likely contains the Lifitegrast ophthalmic solution. One hand holds the packet while the other peels it open, demonstrating the proper method to access the single-use dose.*

FDA Label Image

Lifitegrast Ophthalmic Solution 5% Figure-6 (Lifitegrast Fig6)

An instructional line drawing showing a pair of hands opening a foil pouch, labeled Figure D. This illustration likely demonstrates how to open the packaging of Lifitegrast ophthalmic solution for use.*

FDA Label Image

Lifitegrast Ophthalmic Solution 5% Figure-7 (Lifitegrast Fig7)

An instructional illustration showing a hand holding a single-use ophthalmic solution dropper bottle, demonstrating correct handling for administration of Lifitegrast ophthalmic solution 50 mg/mL.*

FDA Label Image

Lifitegrast Ophthalmic Solution 5% Figure-8 (Lifitegrast Fig8)

Illustration showing how to hold and use a small ophthalmic solution dropper bottle, demonstrating positioning of the bottle and finger for administration. The image is labeled as Figure F and involves hands holding the bottle and a finger pointing toward the top of the dropper.*

FDA Label Image

Lifitegrast Ophthalmic Solution 5% Figure-9 (Lifitegrast Fig9)

An instructional illustration showing a person holding a single-dose ophthalmic solution ampule, demonstrating how to twist and open the top by holding the base and rotating the top section in opposite directions.*

FDA Label Image

Lifitegrast Ophthalmic Solution 5% Figure1 (Lifitegrast Str)

Chemical structure of the active ingredient Lifitegrast as shown in the image. The structure includes multiple rings and functional groups, such as chlorides and a sulfonyl methyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.